NU-101 / Nuclidium - LARVOL DELTA

NUCLIDIUM Announces First Patient Imaged in Phase 1 Study Evaluating 61Cu-based Radiotracer in Patients with PSMA-positive Prostate Cancer (Businesswire) - "61Cu-NuriPro (61Cu-NODAGA-PSMA I&T) is the diagnostic component of NUCLIDIUM’s NuriPro program, binding specifically to Prostate Specific Membrane Antigen...61Cu-NuriPro is the first candidate from the company’s innovative copper-based radiopharmaceutical pipeline to enter the clinic...Its theranostic counterpart, 67Cu-NuriPro (67Cu-NODAGA-PSMA I&T), for the treatment of patients with certain types of prostate cancer, is currently completing its preclinical program. A phase 1 clinical study is planned to start in 2025."

Trial status • Prostate Cancer